ZEN 3694
Alternative Names: BETi ZEN-3694; ZEN-003694; ZEN-3694Latest Information Update: 06 Sep 2024
At a glance
- Originator University of Pittsburgh; Zenith Epigenetics
- Developer National Cancer Institute (USA); Newsoara Biopharma; Pfizer; Zenith Epigenetics
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Phase I/II Carcinoma; Lymphoma
- No development reported Haematological malignancies; Lung cancer
Most Recent Events
- 20 Aug 2024 National Cancer Institute suspends phase-I trial in Solid tumours and Triple-negative breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) due to pending amendment (NCT05111561)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Research (AACR-2024)
- 07 Mar 2024 Zenith Epigenetics in collaboration with Pfizer and Newsoara Biopharma terminates a phase II trial in Triple-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO), due to the results from an interim futility analysis (NCT03901469) (EudraCT2018-003906-26)